Another Alzheimer's Setback As Roche And Lilly Drugs Fail
Fresh Disappointment For Amyloid Hypothesis
Executive Summary
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.
You may also be interested in...
Roche Partners With UCB On Anti-Tau Alzheimer’s Drug
UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.
Keeping Track: Biogen’s Aducanumab Headlines Midsummer Submission Round-Up
The latest application submission news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Alzheimer’s Drug Coverage Issues Move To Forefront With Biogen’s Plan To Seek Approval
Any product would be mostly covered by Medicare, but because the potential patient population will likely be 'substantial,' payers will likely 'closely scrutinize' these drugs, Duke Margolis white paper observes.